How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
F El Chaer, JJ Auletta… - Blood, The Journal of the …, 2022 - ashpublications.org
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies.
F El Chaer, JJ Auletta, RF Chemaly - Blood, 2022 - europepmc.org
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
F El Chaer, JJ Auletta, RF Chemaly - Blood, 2022 - mdanderson.elsevierpure.com
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
[HTML][HTML] How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
F El Chaer, JJ Auletta, RF Chemaly - Blood, 2022 - Elsevier
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
[HTML][HTML] How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
F El Chaer, JJ Auletta, RF Chemaly - Blood, 2022 - ncbi.nlm.nih.gov
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
F El Chaer, JJ Auletta, RF Chemaly - Blood, 2022 - pubmed.ncbi.nlm.nih.gov
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies.
F El Chaer, JJ Auletta, RF Chemaly - Blood, 2022 - europepmc.org
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …